[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acne-scars---atrophic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acne-scars---atrophic":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,49,71,93],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":5},"100639796","safety-and-efficacy-evaluation-of-the-radiofrequency-therapeutic-device-for-the-treatment-of-atrophic-acne-scars-100639796",false,"NCT07620769","Safety and Efficacy Evaluation of the Radiofrequency Therapeutic Device for the Treatment of Atrophic Acne Scars","A Prospective, Multicenter, Randomized, Parallel-Controlled, Blinded-Assessment, Non-Inferiority Clinical Trial to Evaluate the Safety and Effectiveness of a Radiofrequency Therapeutic Device for the Treatment of Atrophic Acne Scars","Inclusion Criteria:\n\n1. Participants aged 18 to 65 years at the time of written informed consent.\n2. Participants with Fitzpatrick skin types II to V.\n3. Participants with facial atrophic acne scars and an ECCA score ≥60 as assessed by the investigator.\n4. Participants who are able to understand the purpose and procedures of the study, voluntarily agree to participate, and provide written informed consent.\n\nExclusion Criteria:\n\n1. Participants with a history of facial surgery or cosmetic surgical procedures, or those planning to undergo cosmetic surgical treatment during the study period, which in the investigator's judgment may increase treatment risk or affect efficacy evaluation, including any of the following:\n2. Participants with active or progressive skin diseases in the treatment area, or skin diseases associated with the Koebner phenomenon, such as eczema, psoriasis vulgaris, lichen planus, or vitiligo, which in the investigator's judgment may affect treatment or evaluation.\n3. Participants with open wounds, malignant or unspecified skin tumors, precancerous lesions, or viral, bacterial, or fungal infections in the treatment area, including herpes simplex, verruca vulgaris, verruca plana, cutaneous tuberculosis, or mycobacterial infections.\n4. Participants with scars, tattoos, piercings, excessive hair, or other conditions in the treatment area that, in the investigator's judgment, may interfere with treatment or evaluation.\n5. Participants with impaired skin barrier function in the treatment area that, in the investigator's judgment, may increase treatment risk or affect efficacy evaluation.\n6. Participants with a history of excessive sun exposure within 1 month prior to screening that, in the investigator's judgment, may increase treatment risk or affect efficacy evaluation.\n7. Participants with known hypersensitivity or allergy to lidocaine, other local anesthetics, or any device or medication components used in this study.\n8. Participants with severe hepatic or renal dysfunction, serious disease of other major organs, or uncontrolled diabetes mellitus.\n9. Participants with abnormal coagulation function during screening, use of medications affecting platelet or coagulation function, or platelet count below the lower limit of normal.\n10. Participants with active autoimmune disease or a history of autoimmune disease, including systemic lupus erythematosus, rheumatoid arthritis, scleroderma, or dermatomyositis.\n11. Participants with a history of keloid formation.\n12. Participants diagnosed with psychiatric disorders or active anxiety or depression that may impair the ability to understand or comply with study requirements.\n13. Participants with metallic implants such as cardiac pacemakers or implantable cardioverter-defibrillators.\n14. Participants planning pregnancy during the study period or unwilling to use medically acceptable contraception methods.\n15. Participants who are pregnant or breastfeeding.\n16. Participants who participated in another clinical trial involving a drug and\u002For medical device within 1 month prior to enrollment.\n17. Participants considered unsuitable for participation by the investigator for any other reason.",true,"ALL","18 Years","65 Years",{"count":21,"type":22},252,"ESTIMATED","INTERVENTIONAL",[25],"NA","The objective of this clinical trial is to evaluate the safety and effectiveness of a radiofrequency treatment device for the treatment of atrophic acne scars.\n\nThis is a prospective, multicenter, randomized, parallel-controlled, blinded-assessment, non-inferiority trial design.\n\nThe study aims to evaluate the effectiveness and safety of the radiofrequency therapeutic device manufactured by Sponsor for the treatment of atrophic acne scars, in comparison with the control device, the radiofrequency therapeutic device.\n\nParticipants will receive treatment sessions using either the investigational device or the control device, undergo follow-up evaluations after treatment to assess efficacy and safety outcomes.\n\nThe primary endpoint is Improvement in atrophic acne scars measured by the ECCA score compared with baseline, assessed 12 weeks after the final treatment.\n\nThe secondary efficacy endpoints include Global Aesthetic Improvement Scale (GAIS), Study Participant Satisfaction Assessment, Pain Score, Changes in skin characteristics compared with baseline Safety evaluations include Adverse events (AEs), Serious adverse events (SAEs)",[28,29,30,31],"Acne Scars","Acne Scars - Atrophic","Acne Scar","Acne Scarring",[33,34,35,36],"acne scar","atrophic acne scar","radiofreqency device","Radiofrequency Therapeutic Device","NOT_YET_RECRUITING","2026-05-29",{"date":40,"type":41},"2026-06-02","ACTUAL",{"date":43,"type":22},"2026-06",{"date":45,"type":22},"2027-10",{"name":47,"class":48},"CLASSYS Inc.","INDUSTRY",{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100629221","efficacy-and-safety-of-combined-nanofat-injection-with-either-platelet-rich-fibrin-or-microneedling-versus-nanofat-injection-alone-in-the-treatment-of-facial-atrophic-post-acne-scars-100629221","NCT07471854","Efficacy and Safety of Combined Nanofat Injection With Either Platelet Rich Fibrin or Microneedling Versus Nanofat Injection Alone in the Treatment of Facial Atrophic Post Acne Scars","Inclusion Criteria:\n\n* Patients older than 18 years of both sexes with moderate to severe atrophic facial acne scars on both cheeks\n\nExclusion Criteria:\n\n* 1\\. Patients' age \\\u003C18 or \\>45 years 2. Pregnant and lactating women 3. active inflammatory acne or active infection in the treatment area. 4. treatment of the targeted study sites within 2 months 5. history of chronic diseases (autoimmune diseases, bleeding disorders, taking anticoagulant therapy or aspirin) 6. history of hypertrophic scars or keloid formation tendency. 7. patients with unrealistic expectations.","45 Years",{"count":57,"type":22},42,[25],"To compare the efficacy and safety of combined nanofat injection with either platelet rich fibrin or microneedling versus nanofat injection alone in the treatment of facial atrophic post acne scars.",[29],"2026-03-16",{"date":63,"type":41},"2026-03-18",{"date":65,"type":22},"2026-05-01",{"date":67,"type":22},"2027-12-01",{"name":69,"class":70},"Assiut University","OTHER",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":78,"maxAge":55,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":4},"100600243","efficacy-of-stromal-vascular-fraction-on-acne-scar-correction-100600243","NCT07094958","Efficacy of Stromal Vascular Fraction on Acne Scar Correction","Efficacy of Intradermal Stromal Vascular Fraction Injection in the Treatment of Atrophic Acne Scar","Inclusion Criteria:\n\n* Age between 19 and 45 years\n* Presence of bilateral atrophic acne scars (boxcar, rolling, or icepick types) on the face\n* Willingness to undergo fat harvesting procedure\n* Ability to comply with study visits and follow-up\n* Written informed consent obtained\n\nExclusion Criteria:\n\n* Active acne lesions on the treatment area\n* History of keloid or hypertrophic scarring\n* Prior treatment for acne scars (e.g., laser, filler, microneedling) within the past 6 months\n* History of systemic immunosuppressive therapy within the past 3 months\n* Pregnant or breastfeeding women\n* Any systemic disease that may interfere with wound healing or safety assessment (e.g., uncontrolled diabetes, collagen vascular disease)","19 Years",{"count":80,"type":22},16,[25],"This study aims to evaluate the efficacy and safety of intradermal injection of autologous stromal vascular fraction (SVF) in the treatment of atrophic acne scars. SVF is a heterogeneous cell population derived from adipose tissue, containing various regenerative and immunomodulatory cells, including mesenchymal stem cells, endothelial progenitor cells, and pericytes.\n\nIn this prospective, randomized, split-face clinical trial, participants with atrophic acne scars will receive SVF injections on one side of the face and normal saline (NS) injections on the contralateral side as a control. Clinical efficacy will be assessed through blinded scar counts, digital imaging, and histological evaluations including epidermal and dermal regenerative markers. The study is designed to investigate whether SVF provides superior clinical improvement compared to placebo.",[28,29],"2025-07-29",{"date":86,"type":41},"2025-07-31",{"date":88,"type":22},"2025-07",{"date":90,"type":22},"2026-07",{"name":92,"class":70},"Seoul National University Hospital",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":23,"phases":103,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":116},"100556354","stromal-vascular-fraction-enriched-prp-in-treatment-of-post-acne-scars-100556354","NCT06524011","Stromal Vascular Fraction Enriched PRP in Treatment of Post-acne Scars","Split Face Comparative Study of Stromal Vascular Fraction Enriched PRP Versus Each Alone in Treatment of Atrophic Post-acne Scars","Inclusion Criteria:\n\n* patients with atrophic post acne scars without any previous treatment trials.\n* adequate blood picture, no anemia, no bleeding or platelet disorders.\n\nExclusion Criteria:\n\n* pregnant and lactating females.\n* elderly.\n* patients with bleeding tendencies.","40 Years",{"count":102,"type":22},30,[25],"in a split face fashion, 30 patients will be randomized into 3 groups: Group A: rt side treated with SVF enriched PRP, lt side treated with prp Group B: rt side treated with SVF enriched PRP, lt side treated with SVF Group C: rt side treated with PRP, lt side treated with SVF",[29],"2024-07-24",{"date":108,"type":41},"2024-07-29",{"date":110,"type":22},"2024-12",{"date":112,"type":22},"2026-02",{"name":114,"class":115},"Zagazig University","OTHER_GOV",1]